Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): Increasing cellular potency through optimization of a distal heteroaromatic group

Journal of Medicinal Chemistry

Volumn 53, Issue 7, 2010, Pages 2741-2756

  Suijkerbuijk, Bart M J M ^a   Niculescu Duvaz, Ion ^a   Gaulon, Catherine ^a   Dijkstra, Harmen P ^a   Niculescu Duvaz, Dan ^a   Ménard, Delphine ^a   Zambon, Alfonso ^a   Nourry, Arnaud ^a   Davies, Lawrence ^a   Manne, Helen A ^a   Friedlos, Frank ^a   Ogilvie, Lesley M ^a   Hedley, Douglas ^a   Lopes, Filipa ^a   Preece, Natasha P U ^a   Moreno Farre, Javier ^a   Raynaud, Florence I ^a   Kirk, Ruth ^a   Whittaker, Steven ^a   Marais, Richard ^a   Springer, Caroline J ^a   more..

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 N 3 TOLYL 3 TERT BUTYLPYRAZOL 5 YL) 3 [4 (2 OXO 2,3 DIHYDRO 1H IMIDAZO [4,5 B] PYRIDIN 7 YL OXY) NAPHTHALEN 1 YL] UREA; 1 (1 N 4 TOLYL 3 TERT BUTYLPYRAZOL 5 YL) 3 [4 (2 OXO 2,3 DIHYDRO 1 N METHYL 1H IMIDAZO [4,5 B] PYRIDIN 7 YL OXY)NAPHTHALEN 1 YL] UREA; 1 (3 TERT BUTYL 1 4 TOLYL 1H PYRAZOL 5 YL) 3 [4 (2 OXO 2,3 DIHYDRO 1H IMIDAZO [4,5 B] PYRIDIN 7 YLOXY) PHENYL] UREA; 1 [1 N (4 FLUOROPHENYL) 3 TERT BUTYLPYRAZOL 5 YL] 3 [4 (2 OXO 2,3 DIHYDRO 1 N METHYL 1H IMIDAZO [4,5 B] PYRIDIN 7 YL OXY) NAPHTALEN 1 YL] UREA; 1 [3 TERT BUTYL 1 (4 FLUOROPHENYL) 1H PYRAZOL 5 YL] 3 [4 (2 OXO 2,3 DIHYDRO 1H IMIDAZO [4,5 B] PYRIDIN 7 YL OXY) NAPHTHALEN 1 YL] UREA; 3 TERT BUTYL 1 ARYL 1H PYRAZOLE DERIVATIVE; AROMATIC COMPOUND; B RAF KINASE; B RAF KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; MELANOMA; MOUSE; NONHUMAN; SARCOMA; STRUCTURE ACTIVITY RELATION; VIRUS ONCOGENE;

ANIMALS; CELL LINE, TUMOR; DRUG DESIGN; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; ONCOGENE PROTEINS V-RAF; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SARCOMA VIRUSES, MURINE; SEQUENCE HOMOLOGY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950559038     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm900607f     Document Type: Article

References (37)

1. Weinberg, R. A. The Biology of Cancer; Garland Science, Taylor & Francis Group, LLC: New York, 2007; pp 173 - 176.
2. Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer Oncogene 2007, 26 (22) 3279 - 3290
3. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, N.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W. C.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Siegler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in human cancer Nature 2002, 417 (6892) 949 - 954
4. Gray-Schopfer, V.; Wellbrock, C.; Marais, R. Melanoma biology and new targeted therapy Nature 2007, 445 (7130) 851 - 857
5. Wan, P. T. C.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R.; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116 (6), 855 - 867.
6. Dhanasekaran, D. N.; Johnson, G. L. MAPKs: function, regulation, role in cancer and therapeutic targeting Oncogene 2007, 26 (22) 3097 - 3099
7. Sebolt-Leopold, J. S. Development of anticancer drugs targeting the MAP kinase pathway Oncogene 2000, 19 (56) 6594 - 6599
8. Sebolt-Leopold, J. S.; Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer Nat. Rev. Cancer 2004, 4 (12) 937 - 947
9. Karasarides, M.; Chiloeches, A.; Hayward, R.; Niculescu-Duvaz, D.; Scanlon, I.; Friedlos, F.; Ogilvie, L.; Hedley, D.; Martin, J.; Marshall, C. J.; Springer, C. J.; Marais, R. B-RAF is a therapeutic target in melanoma Oncogene 2004, 23 (37) 6292 - 6298
10. Roberts, P. J.; Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 2007, 26 (22) 3291 - 3310
11. Sebolt-Leopold, J. S. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway Clin. Cancer Res. 2008, 14 (12) 3651 - 3656
12. Khazak, V.; Astsaturov, I.; Serebriiskii, I. G.; Golemis, E. A. Selective Raf inhibition in cancer therapy Expert Opin. Ther. Targets 2007, 11 (12) 1587 - 1609
13. Lowinger, T. B.; Riedl, B.; Dumas, J.; Smith, R. A. Design and discovery of small molecules targeting Raf-1 kinase Curr. Pharm. Des. 2002, 8 (25) 2269 - 2278
14. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R. A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat. Rev. Drug Discovery 2006, 5 (10) 835 - 844
15. Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L. Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Bioorg. Med. Chem. Lett. 2001, 11 (14) 1911 - 1914
16. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat. Med. 1996, 2 (5) 561 - 566
17. Zimmermann, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N. B. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives Bioorg. Med. Chem. Lett. 1997, 7 (2) 187 - 192
18. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (ST1571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discovery 2002, 1 (7) 493 - 502
19. Moyer, J. D.; Barbacci, E. G.; Iwata, K. K.; Arnold, L.; Boman, B.; Cunningham, A.; DiOrio, C.; Doty, J.; Morin, M. J.; Moyer, M. P.; Neveu, M.; Pollack, V. A.; Pustilnik, L. R.; Reynolds, M. M.; Sloan, D.; Theleman, A.; Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res. 1997, 57 (21) 4838 - 4848
20. Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J. Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T. C.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3 Z)-ylidenemethyl]-2,4-dimethyl-1 H -pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase J. Med. Chem. 2003, 46 (7) 1116 - 1119 (Pubitemid 36428215)
21. Lombardo, L. J.; Lee, F. Y.; Chen, P.; Norris, D.; Barrish, J. C.; Behnia, K.; Castaneda, S.; Cornelius, L. A.; Das, J.; Doweyko, A. M.; Fairchild, C.; Hunt, J. T.; Inigo, I.; Johnston, K.; Kamath, A.; Kan, D.; Klei, H.; Marathe, P.; Pang, S.; Peterson, R.; Pitt, S.; Schieven, G. L.; Schmidt, R. J.; Tokarski, J.; Wen, M. L.; Wityak, J.; Borzilleri, R. M. Discovery of N -(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J. Med. Chem. 2004, 47 (27) 6658 - 6661
22. Garnett, M. J.; Marais, R. Guilty as charged: B-RAF is a human oncogene Cancer Cell 2004, 6 (4) 313 - 319
23. Niculescu-Duvaz, I.; Roman, E.; Whittaker, S. R.; Friedlos, F.; Kirk, R.; Scanlon, I. J.; Davies, L. C.; Niculescu-Duvaz, D.; Marais, R.; Springer, C. J. Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead J. Med. Chem. 2006, 49 (1) 407 - 416
24. Niculescu-Duvaz, I.; Roman, E.; Whittaker, S.; Friedlos, F.; Kirk, R.; Scanlon, I.; Davies, L. C.; Niculescu-Duvaz, D.; Marais, R.; Springer, C. J. Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold J. Med. Chem. 2008, 51 (11) 3261 - 3274
25. Niculescu-Duvaz, D.; Gaulon, C.; Dijkstra, H. P.; Niculescu-Duvaz, I.; Zambon, A.; Ménard, D.; Suijkerbuijk, B. M. J. M.; Nourry, A.; Davies, L.; Manne, H.; Friedlos, F.; Ogilvie, L.; Hedley, D.; Whittaker, S.; Kirk, R.; Gill, A.; Taylor, R. D.; Raynaud, F. I.; Moreno-Farre, J.; Marais, R.; Springer, C. J. Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF) J. Med. Chem. 2009, 52 (8) 2255 - 2264
26. Ménard, D.; Niculescu-Duvaz, I.; Dijkstra, H. P.; Niculescu-Duvaz, D.; Suijkerbuijk, B. M. J. M.; Zambon, A.; Nourry, A.; Roman, E.; Davies, L.; Manne, H. A.; Friedlos, F.; Kirk, R.; Whittaker, S.; Gill, A.; Taylor, R. D.; Marais, R.; Springer, C. J. Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring J. Med. Chem. 2009, 52 (13) 3881 - 3891
27. Nourry, A.; Zambon, A.; Davies, L.; Niculescu-Duvaz, I.; Dijkstra, H. P.; Ménard, D.; Gaulon, C.; Niculescu-Duvaz, D.; Suijkerbuijk, B. M. J. M.; Friedlos, F.; Manne, H. A.; Kirk, R.; Whittaker, S.; Marais, R.; Springer, C. J. BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring. J. Med. Chem. DOI: 10.1021/jm901509a.
28. Gallou, I.; Eriksson, M.; Zeng, X. Z.; Senanayake, C.; Farina, V. Practical synthesis of unsymmetrical ureas from isopropenyl carbamates J. Org. Chem. 2005, 70 (17) 6960 - 6963
29. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate J. Med. Chem. 2002, 45 (14) 2994 - 3008
30. Whittaker, S.; Marais, R. Unpublished results.
31. Ghose, A. K.; Herbertz, T.; Pippin, D. A.; Salvino, J. M.; Mallamo, J. P. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery J. Med. Chem. 2008, 51 (17) 5149 - 5171
32. Liao, J. J. L. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors J. Med. Chem. 2007, 50 (3) 409 - 424
33. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2006, 2 (7) 358 - 364
34. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267 (3) 727 - 748
35. Smith, N. F.; Hayes, A.; Nutley, B. P.; Raynaud, F. I.; Workman, P. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice Cancer Chemother. Pharmacol. 2004, 54, 475 - 486
36. Nutley, B. P.; Raynaud, F. I.; Wilson, S. C.; Fischer, P.; Hayes, A.; Goddard, P. M.; McClue, S. J.; Jarman, M.; Lane, D. P.; Workman, P. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R -roscovitine in the mouse Mol. Cancer Ther. 2005, 4125 - 4139
37. Workman, P.; Twentyman, P.; Balkwill, F.; Balmain, A.; Chaplin, D.; Double, J.; Embleton, J.; Newell, D.; Raymond, R.; Stables, J.; Stephens, T.; Wallace, J. United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR). Guidelines for the welfare of animals in experimental neoplasia (2 nd ed.). Br. J. Cancer 1998, 77 (1), 1 - 10.